Verastem announced that it has submitted an Orphan Drug Application to the FDA for VS-6063 in mesothelioma. VS-6063 is an oral small molecule inhibitor of focal adhesion kinase (FAK), which is a critical pathway for cancer stem cells. VS-6063 was well-tolerated and demonstrated signs of clinical activity in a Phase 1 study in advanced solid tumors.
VS-6063 is currently in a Phase 1/2 study in patients with advanced ovarian cancer, where VS-6063 is being tested in combination with paclitaxel. It is anticipated that VS-6063 will enter a potentially pivotal study in mesothelioma midyear 2013.
For more information call (617) 252-9300 or visit www.verastem.com